Logan J Harper1, Gabrielle Love2, Rijuta Singh3, Andre Smith1, Daniel A Culver1, J Daryl Thornton4,5. 1. Department of Pulmonology, Respiratory Institute, Cleveland Clinic, Cleveland, Ohio. 2. Mental Health, Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, Ohio. 3. Department of Internal Medicine, Western Reserve Hospital, Cuyahoga Falls, Ohio; and. 4. Center for Reducing Health Disparities and. 5. Division of Pulmonary, Critical Care, and Sleep Medicine, MetroHealth Campus, Case Western Reserve University, Cleveland, Ohio.
Abstract
Rationale: Lower-income patients with sarcoidosis experience worse outcomes than those with higher incomes. The reasons for these disparities are not well understood. Objectives: To identify patient-reported barriers to and facilitators of self-empowered care among patients with sarcoidosis residing in high- and low-median-income zip-code areas. Methods: Patients with biopsy-proven sarcoidosis who had received pharmacologic treatment within the past year and who were cared for in a sarcoidosis clinic of a large, urban medical system were included. Focus groups were stratified by high- and low-median-income zip-code areas. Transcriptions were analyzed using grounded theory. Results: Five focus groups were created; two included patients living in zip-code areas with high median incomes ($84,263; interquartile range [IQR], $79,334-$89,795), and three included patients living in zip-code areas with low median incomes ($27,470; IQR, $22,412-27,597). Patients with sarcoidosis from low-income and high-income zip-code areas reported remarkably similar experiences. Patients reported that sarcoidosis was a burden owing to its disease manifestations and the adverse effects of treatment, which led to a compromised ability to perform their activities of daily living at home or at work. Reported barriers to care included perceived inadequate knowledge about sarcoidosis among providers, communication barriers with providers, and the high cost of treatment. Patients from low-income zip-code areas experienced discrimination related to race and income, which served to compound their mistrust. Patients sought to overcome these barriers through self-empowerment, including independent learning, self-advocacy, medication nonadherence, and use of alternative therapies. Conclusions: Patients with sarcoidosis who lived in high- and low-income zip-code areas expressed similar overall concerns regarding sarcoidosis care. However, patients from low-income zip-code areas more frequently expressed concerns about racial and income-based discrimination. Patients from both groups addressed these barriers through self-empowerment, which included not adhering to prescribed therapies. Future work should focus on the effects of culturally and socioeconomically congruent, community-engaged interventions for quality of life of patients with sarcoidosis.
Rationale: Lower-income patients with sarcoidosis experience worse outcomes than those with higher incomes. The reasons for these disparities are not well understood. Objectives: To identify patient-reported barriers to and facilitators of self-empowered care among patients with sarcoidosis residing in high- and low-median-income zip-code areas. Methods: Patients with biopsy-proven sarcoidosis who had received pharmacologic treatment within the past year and who were cared for in a sarcoidosis clinic of a large, urban medical system were included. Focus groups were stratified by high- and low-median-income zip-code areas. Transcriptions were analyzed using grounded theory. Results: Five focus groups were created; two included patients living in zip-code areas with high median incomes ($84,263; interquartile range [IQR], $79,334-$89,795), and three included patients living in zip-code areas with low median incomes ($27,470; IQR, $22,412-27,597). Patients with sarcoidosis from low-income and high-income zip-code areas reported remarkably similar experiences. Patients reported that sarcoidosis was a burden owing to its disease manifestations and the adverse effects of treatment, which led to a compromised ability to perform their activities of daily living at home or at work. Reported barriers to care included perceived inadequate knowledge about sarcoidosis among providers, communication barriers with providers, and the high cost of treatment. Patients from low-income zip-code areas experienced discrimination related to race and income, which served to compound their mistrust. Patients sought to overcome these barriers through self-empowerment, including independent learning, self-advocacy, medication nonadherence, and use of alternative therapies. Conclusions: Patients with sarcoidosis who lived in high- and low-income zip-code areas expressed similar overall concerns regarding sarcoidosis care. However, patients from low-income zip-code areas more frequently expressed concerns about racial and income-based discrimination. Patients from both groups addressed these barriers through self-empowerment, which included not adhering to prescribed therapies. Future work should focus on the effects of culturally and socioeconomically congruent, community-engaged interventions for quality of life of patients with sarcoidosis.
Entities:
Keywords:
ethnicity and race; healthcare delivery; healthcare disparities; sarcoidosis
Authors: Juan C Celedón; Esteban G Burchard; Dean Schraufnagel; Carlos Castillo-Salgado; Marc Schenker; John Balmes; Enid Neptune; Kristin J Cummings; Fernando Holguin; Kristin A Riekert; Juan P Wisnivesky; Joe G N Garcia; Jesse Roman; Rick Kittles; Victor E Ortega; Susan Redline; Rasika Mathias; Al Thomas; Jonathan Samet; Jean G Ford Journal: Ann Am Thorac Soc Date: 2017-05
Authors: Andrea J Apter; Fei Wan; Susan Reisine; Daniel K Bogen; Cynthia Rand; Bruce Bender; Ian M Bennett; Rodalyn Gonzalez; Chantel Priolo; Seema S Sonnad; Tyra Bryant-Stephens; Monica Ferguson; Rhonda C Boyd; Thomas Ten Have; Jason Roy Journal: J Asthma Date: 2013-07-17 Impact factor: 2.515
Authors: Michelle Sharp; Taylor Brown; Edward S Chen; Cynthia S Rand; David R Moller; Michelle N Eakin Journal: Chest Date: 2020-02-04 Impact factor: 9.410
Authors: Nauman A Khan; Christopher V Donatelli; Adriano R Tonelli; Jonathan Wiesen; Manuel L Ribeiro Neto; Debasis Sahoo; Daniel A Culver Journal: Respir Med Date: 2017-09-08 Impact factor: 3.415
Authors: Jesse D Schold; Laura D Buccini; Michael W Kattan; David A Goldfarb; Stuart M Flechner; Titte R Srinivas; Emilio D Poggio; Richard Fatica; Liise K Kayler; Ashwini R Sehgal Journal: Arch Surg Date: 2012-06
Authors: D L Rabin; B Thompson; K M Brown; M A Judson; X Huang; D T Lackland; G L Knatterud; H Yeager; C Rose; J Steimel Journal: Eur Respir J Date: 2004-10 Impact factor: 16.671